MedTrace Logo

Safety and Efficacy of CERE-120 in Subjects With Parkinson's Disease

NCT00985517 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 57

Last updated 2020-04-16

Study results available
· View outcomes & findings →

Summary

The purpose of this study was to evaluate the safety and potential benefits of CERE-120 in the treatment of Parkinson's disease.

Conditions

  • Idiopathic Parkinson's Disease

Interventions

BIOLOGICAL

CERE-120: Adeno-Associated Virus Delivery of Neurturin

PROCEDURE

Sham Surgery

Sponsors & Collaborators

  • Sangamo Therapeutics

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
35 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-10-29
Primary Completion
2014-11-09
Completion
2017-11-16

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00985517 on ClinicalTrials.gov